Technical aspects and intraoperative factors influencing the efficiency of non-penetrating deep sclerectomy and implantation of PreserFlo MicroShunt Artykuł przeglądowy

Abstrakt

Glaucoma is a neurodegenerative disorder marked by the death of retinal ganglion cells which causes characteristic vision field loss. At the moment the only well-known risk factor for progression of the glaucoma is intraocular pressure. In this regard the lowering of intraocular pressure became the main focus of treatment.

Different types of glaucoma surgeries have developed over the last decades. Most of them facilitate outflow of aqueous humor, few decrease the production. This article takes into account two of them: non-penetrating deep sclerectomy and implantation of PreserFlo MicroShunt.

Deep sclerectomy is a well established non-penetrating type of glaucoma surgery. With use of adjuvant methods such as use of space-maintaining implants, use of viscoelastic agent and use of antimetabolites during procedure it allowed to achieve success rate of standard penetrating surgery with lower rate of complications.

PreserFlo MicroShunt implantation is a promising new filtration procedure for glaucoma treatment. First published studies show promising efficacy and safety outcomes, although further research is needed.